Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Kiniksa Pharmaceuticals stock

Learn how to easily invest in Kiniksa Pharmaceuticals stock.

Kiniksa Pharmaceuticals is a biotechnology business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Kiniksa Pharmaceuticals employs 215 staff and has a trailing 12-month revenue of around $177 million.

How to buy Kiniksa Pharmaceuticals stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – KNSA. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Kiniksa Pharmaceuticals stock price (NASDAQ: KNSA)

Use our graph to track the performance of KNSA stocks over time.

Kiniksa Pharmaceuticals shares at a glance

Information last updated 2023-01-26.
Latest market close$13.99
52-week range$7.36 - $17.20
50-day moving average $15.34
200-day moving average $12.00
Wall St. target price$22.20
PE ratio 6.9453
Dividend yield $0 (0%)
Earnings per share (TTM) $2.01

Buy Kiniksa Pharmaceuticals stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Kiniksa Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kiniksa Pharmaceuticals price performance over time

Historical closes compared with the close of $13.99 from 2023-01-27

1 week (2023-01-23) -0.07%
1 month (2022-12-30) -6.61%
3 months (2022-10-31) 22.50%
6 months (2022-07-29) 41.17%
1 year (2022-01-31) 24.58%
2 years (2021-01-29) -28.95%
3 years (2020-01-31) 14.71
5 years (2018-01-27) N/A

Is Kiniksa Pharmaceuticals stock undervalued or overvalued?

Valuing Kiniksa Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kiniksa Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Kiniksa Pharmaceuticals's P/E ratio

Kiniksa Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Kiniksa Pharmaceuticals shares trade at around 7x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Kiniksa Pharmaceuticals financials

Revenue TTM $177 million
Gross profit TTM $28.6 million
Return on assets TTM -5.68%
Return on equity TTM 47.68%
Profit margin 80.53%
Book value $5.52
Market capitalisation $970.7 million

TTM: trailing 12 months

Kiniksa Pharmaceuticals share dividends

We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.

Kiniksa Pharmaceuticals share price volatility

Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $7.36 up to $17.195. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is -0.0917. This would suggest that Kiniksa Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Kiniksa Pharmaceuticals has bucked the trend.

Kiniksa Pharmaceuticals overview

Kiniksa Pharmaceuticals, Ltd. , a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda. .

Frequently asked questions

What percentage of Kiniksa Pharmaceuticals is owned by insiders or institutions?
Currently 1.923% of Kiniksa Pharmaceuticals shares are held by insiders and 46.04% by institutions.
How many people work for Kiniksa Pharmaceuticals?
Latest data suggests 215 work at Kiniksa Pharmaceuticals.
When does the fiscal year end for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals's fiscal year ends in December.
Where is Kiniksa Pharmaceuticals based?
Kiniksa Pharmaceuticals's address is: Clarendon House, Hamilton, Bermuda, HM 11
What is Kiniksa Pharmaceuticals's ISIN number?
Kiniksa Pharmaceuticals's international securities identification number is: BMG5269C1010
What is Kiniksa Pharmaceuticals's CUSIP number?
Kiniksa Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: G5269C101

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site